CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance cancer treatment options by developing innovative immunotherapeutic drugs that activate the immune system. It focuses on translating preclinical findings into clinical applications, particularly through the use of agonist antibodies.
This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system.
The recent FDA-approval of Ipilimumab demonstrated that cancer immunotherapeutics constitute a clinically effective, marketable drug concept.
Ipilimumab is an antagonist…
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Heidelberg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Southampton
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Pamplona
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
